Phytoestrogen dietary supplementation in post-menopausal women with type two diabetes: effects on glycaemic control, insulin resistance and indices of cardiovascular risk. A cross over trial

ISRCTN ISRCTN75939563
DOI https://doi.org/10.1186/ISRCTN75939563
Protocol serial number Protocol LREC 11/01/207
Sponsor Hull University (UK)
Funder This trial is internally funded by Hull University, Medical Department, Diabetes and Endocrinology (UK)
Submission date
16/11/2006
Registration date
14/12/2006
Last edited
18/12/2013
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Nutritional, Metabolic, Endocrine
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Prof Stephen L Atkin
Scientific

Diabetes Centre
HS Brocklehurst Building
220-236 Anlaby Road
Hull
HU3 2RW
United Kingdom

Study information

Primary study designInterventional
Study designCross over, double blind, placebo controlled trial
Secondary study designRandomised controlled trial
Scientific title
Study objectivesThe prevalence of type two diabetes in the UK is increasingly high. Most women with type two diabetes have an increased risk of cardiovascular diseases due to obesity, estrogen depletion, abnormal lipid profile, and endothelial dysfunction amongst others. Recent studies have suggested that dietary supplementation with soy protein combined with isoflavone have a beneficial effect in both glycaemic control and indices of cardiovascular risk. However, it remains unclear if this effect is due to soy protein or isoflavones. The aim of this study is clarify this.

Hypothesis:
Isoflavone supplementation alone has beneficial effects on glycaemic control, insulin resistance and cardiovascular risk factors in post-menopausal patients with diet controlled type two diabetes.
Ethics approval(s)Hull and East Yorkshire Local Ethics Committee, June 2002 (ref: LREC 11/01/207).
Health condition(s) or problem(s) studiedType two diabetes in post-menopausal women
InterventionA tablet containing 66 mg of soy isoflavones or an identical microcrystalline cellulose tablet (placebo) will be given twice daily.

The patients will receive either placebo/isoflavone tablet for three months and after a period of four weeks washout they receive the other (cross over trial) for a further three months.
Intervention typeDrug
PhaseNot Specified
Drug / device / biological / vaccine name(s)Soy isoflavones
Primary outcome measure(s)

1. Modification of glycaemic parameters
2. Modification of indices of cardiovascular risk

Key secondary outcome measure(s)

1. Alteration in renal function
2. Alteration in endogenous sex hormones

Completion date01/03/2004

Eligibility

Participant type(s)Patient
Age groupAdult
SexFemale
Target sample size at registration36
Key inclusion criteria1. Post-menopausal women (amenorrhoea for at least 12 months)
2. Type two diabetes on diet alone as a form of treatment
Key exclusion criteria1. Secondary causes of impaired glucose tolerance such as hypercortisolemia
2. No hormone replacement or stopped at least six weeks prior recruitment
3. Uncontrolled hypothyroidism (if receiving thyroid hormone replacement, the patient should be euthyroid with Thyroid Stimulating Hormones [TSH] less than 5.0 mU/L)
4. Blood pressure more than 160/90 mmHg
5. Recent initiation of statin treatment/dose modification (less than four weeks)
6. Patients not wishing to allow disclosure to General Practitioners (GPs)
Date of first enrolment01/07/2002
Date of final enrolment01/03/2004

Locations

Countries of recruitment

  • United Kingdom
  • England

Study participating centre

Diabetes Centre
Hull
HU3 2RW
United Kingdom

Results and Publications

Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 01/07/2007 Yes No